RIGL vs. INVA, DVAX, MNKD, NVAX, OPK, GERN, RGLS, MYGN, ZBIO, and EBS
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry.
Rigel Pharmaceuticals vs. Its Competitors
Innoviva (NASDAQ:INVA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for Innoviva. Rigel Pharmaceuticals' average media sentiment score of 0.51 beat Innoviva's score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
Innoviva has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
99.1% of Innoviva shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 2.3% of Innoviva shares are held by company insiders. Comparatively, 9.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Innoviva currently has a consensus price target of $55.00, indicating a potential upside of 186.46%. Rigel Pharmaceuticals has a consensus price target of $36.40, indicating a potential upside of 92.44%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts plainly believe Innoviva is more favorable than Rigel Pharmaceuticals.
Innoviva has higher revenue and earnings than Rigel Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rigel Pharmaceuticals has a net margin of 18.31% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat Rigel Pharmaceuticals' return on equity.
Summary
Rigel Pharmaceuticals beats Innoviva on 8 of the 15 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RIGL) was last updated on 7/3/2025 by MarketBeat.com Staff
